Psychedelic Therapy: A Primer for Primary Care Clinicians-Ketamine.
Study Goal
The researchers aimed to evaluate ketamine's therapeutic potential, safety profile, and efficacy in treating depression, PTSD, suicidal ideation, and chronic pain.
Results Summary
Ketamine demonstrated rapid antidepressant effects (effect size d = 0.96 at 24 hours), reduced PTSD symptoms (-11.88 points vs. control), and decreased suicidal ideation (-4.96 points vs. control), though effects often subsided within weeks. It also showed opioid-sparing benefits in pain management but posed risks like cognitive impairment, liver toxicity, and bladder inflammation.
Population
Patients with treatment-resistant depression, major depressive disorder with suicidal ideation, PTSD, and those undergoing postoperative pain management.
Effective Dosage
Single 0.5 mg/kg intravenous infusion (for depression), repeated infusions (for PTSD).
Duration
Acute (single infusion) to repeated administrations over weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ketamine | decrease | cognition, particularly affecting episodic and working memory | - | - | dose-dependent impacts on | #1 |
ketamine | increase | liver toxicity | - | - | poses potential | #2 |
ketamine | increase | "ketamine cystitis," characterized by bladder inflammation | - | - | association with | #3 |
a single intravenous infusion of ketamine | increase | antidepressant effects | - | weighted effect size averages of depression scores (N = 518) following a single 0.5 mg/kg infusion of ketamine is d = 0.96 at 24 hours | exhibits | #4 |
ketamine | decrease | posttraumatic stress disorder (PTSD) symptom severity | - | Clinician-Administered PTSD Scale scores: -11.88 points compared with midazolam control | effective at reducing | #5 |
ketamine | decrease | suicidal ideation | in emergency settings | Scale for Suicidal Ideation scores: -4.96 compared with midazolam control | decreased | #6 |
ketamine | decrease | analgesic consumption | - | - | revolutionized postoperative pain management by reducing | #7 |
ketamine | increase | recovery | - | - | enhancing | #8 |
ketamine | decrease | suicidality and depressive symptoms | - | - | sustain decreases in | #9 |
BACKGROUND: Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid-onset, well-understood cardiovascular effects and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the Food and Drug Administration in 2019 for both treatment-resistant depression and major depressive disorder with suicidal ideation. AREAS OF UNCERTAINTY: Research indicates dose-dependent impacts on cognition, particularly affecting episodic and working memory following both acute administration and chronic use, albeit temporarily for the former and potentially persistent for the latter. Alongside acute risks to cardiovascular stability, ketamine use poses potential liver toxicity concerns, especially with prolonged or repeated exposure within short time frames. The drug's association with "ketamine cystitis," characterized by bladder inflammation, adds to its profile of physiological risks. THERAPEUTIC ADVANCES: Data demonstrate a single intravenous infusion of ketamine exhibits antidepressant effects within hours (weighted effect size averages of depression scores (N = 518) following a single 0.5 mg/kg infusion of ketamine is d = 0.96 at 24 hours). Ketamine is also effective at reducing posttraumatic stress disorder (PTSD) symptom severity following repeated infusions (Clinician-Administered PTSD Scale scores: -11.88 points compared with midazolam control). Ketamine also decreased suicidal ideation in emergency settings (Scale for Suicidal Ideation scores: -4.96 compared with midazolam control). Through its opioid-sparing effect, ketamine has revolutionized postoperative pain management by reducing analgesic consumption and enhancing recovery. LIMITATIONS: Many studies indicate that ketamine's therapeutic effects may subside within weeks. Repeated administrations, given multiple times per week, are often required to sustain decreases in suicidality and depressive symptoms. CONCLUSIONS: Ketamine's comprehensive clinical profile, combined with its robust effects on depression, suicidal ideation, PTSD, chronic pain, and other psychiatric conditions, positions it as a substantial contender for transformative therapeutic application.